Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy

British Journal of Dermatology

Volumn 155, Issue 6, 2006, Pages 1191-1196

  Markham, T ^a   Mathews, C ^b   Rogers, S ^b   Mullan, R ^b   Bresnihan, B ^b   FitzGerald, O ^b   Veale, D J ^b   Fearon, U ^b  

^a Merlin Park University Hospital   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Angiogenesis; Infliximab; Keratinocytes; Psoriasis; Survivin

Indexed keywords

INFLIXIMAB; INHIBITOR OF APOPTOSIS PROTEIN; MESSENGER RNA; SURVIVIN;

ADULT; ARTICLE; CELL NUCLEUS MEMBRANE; CLINICAL ARTICLE; DOWN REGULATION; DRUG EFFECT; DRUG INFUSION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; KERATINOCYTE; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY TRACT INFECTION; SCORING SYSTEM; SKIN BIOPSY; STAINING; THERAPY EFFECT;

ADULT; ANTIBODIES, MONOCLONAL; APOPTOSIS; BIOPSY; DOWN-REGULATION; ENDOTHELIAL CELLS; FEMALE; HUMANS; KERATINOCYTES; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PSORIASIS; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33750914270     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07522.x     Document Type: Article

References (29)

1. Krueger JG, Bowen A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005; 64:30-6.
2. Braverman IM, Yen A. Microcirculation in psoriatic skin. J Invest Dermatol 1974; 62:493-502.
3. Fearon U, Griosios K, Fraser A et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 2003; 30:260-8.
4. Darland DC, D'Amore PA. Blood vessel maturation: vascular development comes of age. J Clin Invest 1999; 103:157-68.
5. Bowen AR, Hanks AN, Murphy KJ et al. Proliferation, apoptosis, and survivin expression in keratinocytic neoplasms and hyperplasias. Am J Dermatopathol 2004; 26:177-81.
6. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 8:917-21.
7. Li F, Ambrosini G, Chu EY et al. Control of apoptosis and mitotic spindle checkpoints by survivin. Nature 1998; 396:580-4.
8. Bokarewa M, Lindblad S, Bokarew D, Tarowski A. Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Arthritis Res Ther 2005; 7:349-58.
9. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006; 5:1087-98.
10. Tran J, Master Z, Yu JL et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002; 99:4349-54.
11. Mesri M, Wall NR, Li J et al. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 2001; 108:981-90.
12. Gottlieb AB, Chamian F, Masud S et al. TNF inhibition rapidly down-regulates multiple pro-inflammatory pathways in psoriasis plaques. J Immunol 2005; 175:2721-9.
13. Wakefield PE, James WD, Samlaska CP, Meltzer MS. Tumor necrosis factor. J Am Acad Dermatol 1991; 24:675-85.
14. Paleolog EM, Young S, Stark AC et al. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998; 41:1258-65.
15. Braverman IM, Yen A. Ultrastructure of the capillary loops in the dermal papillae of psoriasis. J Invest Dermatol 1977; 68:53-60.
16. Hull SM, Goodfield M, Wood EJ et al. Active and inactive edges of psoriatic plaques: identification by tracing and investigation by laser-Doppler flowmetry and immunocytochemical techniques. J Invest Dermatol 1989; 92:782-5.
17. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264:569-71.
18. Creamer D, Allen M, Sousa A et al. Altered vascular endothelium integrin expression in psoriasis. Am J Pathol 1995; 147:1661-7.
19. Nickoloff BJ, Mitra RS, Varani J et al. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994; 144:820-8.
20. Moon WS, Tarnawski AS. Nuclear translocation of survivin in hepatocellular carcinoma: a key to cancer cell growth? Hum Pathol 2003; 34:1119-26.
21. Carter BZ, Wang R, Schober WD et al. Targeting survivin expression induces cell proliferation defect and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells. Cell Cycle 2003; 2:488-93.
22. Banno T, Gazel A, Blumenberg M. Pathway-specific profiling identifies the NFκB dependent tumor necrosis factor α regulated genes in epidermal keratinocytes. J Biol Chem 2005; 19:18973-80.
23. Ichikawa H, Takada Y, Murakami A, Aggarwal BB. Identification of a novel blocker of I kappa B alpha kinase that enhances cellular apoptosis and inhibits cellular invasion through suppression of NF-kappaB-regulated gene products. J Immunol 2005; 11:7383-92.
24. Takada Y, Gillenwater A, Ichikawa H et al. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-κB activation. J Biol Chem 2006; 281:5612-22.
25. ten Hove T, van Montfrans C, Peppelenbosch MP et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50:206-11.
26. Catrina AI, Trollmo C, af Klint E et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 2005; 52:61-72.
27. Chiodino CA, Cesinaro M, Ottani D et al. Expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. J Invest Dermatol 1999; 113:415-18.
28. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 2005; 41 (Suppl. 3):S199-203.
29. Smeets TJ, Kraan MC, van Loon ME et al. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003; 48:2155-62.